SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-23-015635
Filing Date
2023-09-12
Accepted
2023-09-12 06:58:32
Documents
16
Period of Report
2023-09-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20230912x8k.htm   iXBRL 8-K 40864
2 EX-99.1 plx-20230912xex99d1.htm EX-99.1 13248
3 GRAPHIC plx-20230912xex99d1001.jpg GRAPHIC 5450
4 GRAPHIC plx-20230912xex99d1002.jpg GRAPHIC 19665
  Complete submission text file 0001558370-23-015635.txt   305182

Data Files

Seq Description Document Type Size
5 EX-101.SCH plx-20230912.xsd EX-101.SCH 3462
6 EX-101.LAB plx-20230912_lab.xml EX-101.LAB 1351
7 EX-101.PRE plx-20230912_pre.xml EX-101.PRE 11107
10 EXTRACTED XBRL INSTANCE DOCUMENT plx-20230912x8k_htm.xml XML 4864
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 231248978
SIC: 2836 Biological Products, (No Diagnostic Substances)